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The majority of patients with chronic myeloid leukemia are success-fully managed with life-long treatment with tyrosine kinaseinhibitors. In patients in chronic phase, other malignancies are
among the most common causes of death, raising concerns on the rela-
tionship between these deaths and the off-target effects of tyrosine kinase
inhibitors. We analyzed the incidence of second primary malignancies,
and related mortality, in 514 chronic myeloid leukemia patients enrolled
in clinical trials in which imatinib was given as first-line treatment. We
then compared the observed incidence and mortality with those expected
in the age- and sex-matched Italian general population, calculating stan-
dardized incidence and standardized mortality ratios. After a median fol-
low-up of 74 months, 5.8% patients developed second primary malignan-
cies. The median time from chronic myeloid leukemia to diagnosis of the
second primary malignancies was 34 months. We did not find a higher
incidence of second primary malignancies compared to that in the age-
and sex-matched Italian general population, with standardized incidence
ratios of 1.06 (95% CI: 0.57–1.54) and 1.61 (95% CI: 0.92–2.31) in males
and females, respectively. Overall, 3.1% patients died of second primary
malignancies. The death rate in patients with second primary malignan-
cies was 53% (median overall survival: 18 months). Among females, the
observed cancer-related mortality was superior to that expected in the
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Introduction
The availability and the extensive use of tyrosine kinase
inhibitors targeting the BCR-ABL protein in patients with
chronic myeloid leukemia (CML) has reduced the rate of
progression from chronic phase to advanced phase.1 As a
consequence, at least 50% of deaths occur in patients in
chronic phase, or in remission,2 raising concerns on the
relationship of such deaths with the off-target effects of
tyrosine kinase inhibitors.3 Although most of the attention
is focused on cardiovascular adverse events,4 other malig-
nancies are the most common cause of death in patients in
chronic phase or in remission.2
Imatinib was the first tyrosine kinase inhibitor devel-
oped for the treatment of CML and is the most extensive-
ly studied. However, it is still unclear whether its
immunomodulatory properties5-11 may affect anti-cancer
immune surveillance in the long-term, or whether its off-
target activity may influence oncosuppressive pathways.
Of note, regardless of the underlying mechanisms, neo-
plastic alterations have been described in multiple tissues
of rats exposed to imatinib.12 Several studies, mainly refer-
ring to imatinib-treated patients, have investigated the risk
of second primary malignancy (SPM) in CML,13-20 with
sometimes contrasting results. Indeed, in comparisons
with the general population, some epidemiological studies
of unselected CML patients reported higher incidences of
SPM18,21 while similar incidences were found in three large
analyses of patients enrolled in clinical trials.14,17,20
Moreover, it is still debated whether CML patients per
se, regardless of the treatment used, might be at higher risk
of SPM,21-24 a condition that might be now unveiled by the
increased survival of patients.
For all these reasons, it is important to retrieve addition-
age- and sex-matched Italian population, with a standardized mortality ratio of 2.41 (95% CI: 1.26 – 3.56).
In conclusion, our analysis of patients with imatinib-treated chronic myeloid leukemia did not reveal a
higher incidence of second primary malignancies; however, the outcome of second primary malignancies
in such patients was worse than expected. Clinicaltrials.gov: NCT00514488, NCT00510926.
Table 1. Characteristics of the patients at diagnosis of chronic myeloid leukemia.
All patients Patients with SPM Patients without SPM P
Patients, N (%) 514 30 (5.8) 484 (94.2)
Males, N (%) 309 (60) 17 (57) 292 (60)
Females, N (%) 205 (40) 13 (43) 192 (40)
Age, years, median (range) 52 (18 – 84) 60 (35 - 77) 51 (18 – 84) 0.002
Sokal score, N (%)
Low 200 (39) 7 (23) 193 (40)
Intermediate 204 (40) 20 (67) 184 (38)
High 110 (21) 3 (10) 107 (22) 0.008
EUTOS score, N (%)
Low 476 (93) 30 (100) 446 (92)
High 38 (7) 0 38 (8) 0.15
ELTS score, N (%)
Low 282 (55) 15 (50) 267 (55)
Intermediate 160 (31) 13 (43) 147 (30)
High 72 (14) 2 (7) 70 (14) 0.23
ECOG performance status ≥ 1, N (%) 108 (21) 10 (33) 98 (20) 0.088
Transcript type, N (%)
b2a2 185 (36) 11 (37) 174 (36)
b3a3 267 (52) 16 (53) 251 (52)
b2a2/b3a2 56 (11) 3 (10) 53 (11)
other 6 (1) 0 6 (1) 0.98
Clonal cytogenetic abnormalities, N (%)* 17 (5) 1 (4.8) 16 (5) 1
Variant translocations, N (%)* 26 (5.1) 3 (10) 23 (4.7) 0.18
Deletion 9q, N (%)* 55 (11) 6 (20) 49 (11) 0.13
Prior hydroxyurea treatment, N (%) 238 (46) 9 (30) 229 (47) 0.088
Imatinib high doses, N (%) 126 (25) 9 (30) 117 (24) 0.51
Prior malignancies, N (%) 25 (4.9) - - -
Follow-up, months, median, (range) 74 (3-99) - - -
*Of evaluable patients. The statistically significant difference observed for Sokal score probably reflects the higher median age of patients with SPM, resulting in a higher pro-
portion of intermediate Sokal risk patients in this group. In addition, no significant statistical difference between patients with or without SPM was observed regarding values of
hemoglobin, white blood cells, eosinophils, basophils, blasts, platelets, and spleen (data not shown). SPM: second primary malignancies; CML: chronic myeloid leukemia; EUTOS:
EUropean Treatment Outcome Study; ELTS: EUTOS Long-Term Survival; ECOG: Eastern Cooperative Study Group.
al data on the potential carcinogenic role of tyrosine
kinase inhibitors,12 on the incidence of other malignancies,
and on their outcome.13-20
We report here on the malignancies observed in a cohort
of 514 evaluable patients with newly diagnosed, chronic
phase CML, treated first-line with imatinib in three multi-
center national studies.
Methods
We performed a retrospective analysis of 559 patients enrolled
in three prospective clinical trials with imatinib front-line in 62
Italian institutions of the Gruppo Italiano Malattie Ematologiche
dell’Adulto (GIMEMA) CML Working Party. Detailed inclusion cri-
teria have been published previously.25-28 Briefly, patients were at
least 18 years old, with a diagnosis of Philadelphia
chromosome/BCR-ABL-positive CML in early chronic phase (6
months or less from diagnosis to starting imatinib; only hydroxy -
urea allowed). All the patients provided written informed consent
before enrollment. The studies were reviewed and approved by
the Internal Review Board of all the participating Institutions, and
performed in accordance with the Declaration of Helsinki. For the
purpose of the present analysis, a specific survey was conducted
in all Centers with a request to review the clinical records of all the
enrolled patients. Overall, 52/62 (84%) Institutions replied to the
survey, and each Center reported on all its patients; overall, data
were collected on 514/559 (92%) patients, 309 (60%) males and
205 (40%) females. Detailed data on all malignancies, prior to and
after the diagnosis of CML, were collected, including:  site, histol-
ogy type, date of diagnosis, therapy (surgery, chemotherapy,
radiotherapy, other), and outcome. Cancers were classified
according to the International Classification of Diseases, version
10 (ICD-10). We excluded non-melanoma skin cancers (ICD-10:
C-44) from the analysis, because of the possible under-reporting of
such neoplasms, and acute leukemias/myelodysplastic syn-
dromes, considering their possible relationship with CML.
Prior malignancies were defined as malignancies diagnosed
before CML, other malignancies denote all malignancies, includ-
ing relapses of prior malignancies, diagnosed after CML. SPM, the
focus of this analysis, are de novo malignancies diagnosed after
CML (thus excluding relapses of prior malignancies). 
Descriptive statistics were used for SPM incidence and mortali-
ty. Means were compared with the t-test and frequencies with the
χ2 test or Fisher exact test, as appropriate. Cumulative incidences
and survival curves were estimated according to the Kaplan-Meier
method. For comparison with the general population, we calculat-
ed the standardized incidence ratio (SIR) and standardized mortal-
ity ratio (SMR), which are based on the ratio between observed
cases and expected cases in the general reference population in the
same period, matched by sex and age (5-year age classes were
considered). We reported the overall ratios (for subjects aged 20-
84 years), rather than those for specific age subgroups, to avoid
selection biases.
Data on cancer incidence and mortality in the general Italian
population were taken in March 2016 from the AIRTUM
(Associazione Italiana Registri TUMori) database ITACAN (AIRTUM
ITACAN: Tumori in Italia, Versione 2.0; http://www.registri-
tumori.it), which covers 51% of the Italian general population,
and reports cancer incidence and mortality rates derived from real,
observed cancer cases. Times to events (patient-years) were calcu-
lated from the date of diagnosis of CML to the date of diagnosis
of the SPM, death, or last contact, whichever came first, for inci-
dence; and to the date of death or last contact, for mortality. 
Results
Patients
Data from 514 patients, 309 (60%) males and 205 (40%)
females, were analyzed. The median age at CML diagno-
sis was 52 (range, 18-84) years. The median follow-up
from diagnosis of CML to death, or last contact, whichev-
er came first, was 74 (range, 3-99) months. The total
patient-years for the incidence calculation were 3011.1
(males and females: 1806.3 and 1204.8 patient-years,
respectively). The total patient-years for the mortality cal-
culation were 3077.7 (males and females: 1849.4 and
1228.3 patient-years, respectively). The characteristics of
the whole cohort of patients and of patients with or with-
out SPM are summarized in Table 1; age at CML diagnosis
was significantly higher in patients with SPM than in
patients without SPM (60 and 51 years, respectively;
P=0.002).  
Malignancies in the follow-up
Overall, other malignancies were observed in 35/514
(6.8%) patients (Tables 2 and 3). Four patients had a
relapse of a malignancy diagnosed before CML (2 bladder
cancers, 1 renal cancer, and 1 breast cancer), and another
patient developed multiple myeloma from a pre-existing
monoclonal gammopathy of undetermined significance.
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Table 2. Malignancies observed in the follow-up and related mortality.
Malignancy type All Second primary 
malignancies malignancies
observed/deaths, observed/deaths, 
N N
Colon 4 / 4 4 / 4
Prostate 3 / 0 3 / 0
Breast 3 / 0 2 / 0
Central nervous system 2 / 2 2 / 2
Pancreas 2 / 2 2 / 2
Bladder 2 / 1 -
Liver 2 / 1§ 2 / 1§
Non-Hodgkin lymphoma 2 / 1 2 / 1
Thyroid 2 / 0 2 / 0
Bile duct 1 / 1 1 / 1
Esophagus 1 / 1 1 / 1
Lung 1 / 1 1 / 1
Kidney 1 / 1 -
Soft tissues 1 / 1 1 / 1
Urethra 1 / 1 1 / 1
Bowel 1 / 0 1 / 0
Endometrium 1 / 0 1 / 0
Stomach 1 / 0 1 / 0
Multiple myeloma 1 / 1 -
Ovary 1 / 1 1 / 1
Rectum 1 / 0 1 / 0
Testis 1 / 0 1 / 0
TOTAL, n 35 / 19 30 / 16
% of all patients (N=514) 6.8 / 3.7 5.8 / 3.1
§The other patient died due to progression of CML to blast phase. Treatment for other
malignancies included chemotherapy in 14 patients, radiotherapy in nine patients,
surgery in 19 patients, and hormonal therapy in one patient
Table 3. Details of malignancies observed during the follow-up of patients with chronic myeloid leukemia. 
ID Age at Sex Prior OM Age at Time Time IM CCyR OM OM Follow-up PM Age at Therapy Status Time
CML Dx HU OM Dx CML Dx - IM - Dose therapy outcome CML Dx – pM Dx of pM of pM pM Dx –
(years) (years) OM Dx OM Dx (mg) Last (years) at CML Dx relapse
(months) (months) contact/death (months)
(months)
1 53 F No Bile duct cancer 56 37 36 400 Yes S Death 44
2 35 F No Breast cancer 38 25 25 400 Yes S, CHT CR 73
3 50 F Yes Breast cancer 54 51 51 800 Yes S, CHT CR 84
4 53 F No Colon cancer 53 3 3 400 No No/palliation Death 4
5 60 F Yes Colon cancer 60 3 3 800 No S, CHT Death 27
6 63 F Yes Colon cancer 65 22 21 800 Yes S Death 27
7 64 M Yes Colon cancer 68 44 43 400 Yes No/palliation Death 50
8 77 M No DLBCL 79 10 9 400 Yes S, RT, CHT CR 74
9 54 F No Endometrial cancer 61 78 76 400 Yes S CR 78
10 56 M No Esophageal cancer 58 23 23 400 Yes RT, CHT Death 37
11 61 M Yes Gastric cancer 65 48 44 400 Yes S CR 91
12 77 F No Hepatocarcinoma 79 13 13 400 Yes No/palliation Stable * 73
13 69 M No Hepatocarcinoma 72 34 34 400 Yes CHT Death 41
14 60 M No Glioblastoma 63 26 26 400 Yes S Death 28
15 61 M No High-grade glioma 64 33 33 400 Yes S, RT, CHT Death 39
16 64 F No Leiomyosarcoma 65 7 7 800 Yes No/palliation Death 8
17 57 M No Lung cancer 60 36 36 400 Yes RT, CHT Death 41
18 64 M Yes Mantle cell lymphoma 65 6 5 400 Yes CHT Death 11
19 65 F Yes Ovarian cancer 71 63 61 800 Yes S, CHT Death 85
20 70 M No Pancreatic cancer 72 11 10 400 Yes No/palliation Death 15
21 60 F No Pancreatic cancer 67 80 80 800 Yes No/palliation Death 82
22 75 M No Prostatic cancer 77 10 9 400 Yes S CR 72
23 69 M No Prostatic cancer 74 42 42 800 Yes S CR 87
24 54 M No Prostatic cancer 60 62 61 400 Yes S CR 87
25 52 F No Rectal cancer 58 71 70 400 Yes S CR 84
26 58 M No Small bowel cancer 65 79 78 400 Yes S CR 79
27 35 M Yes Testis cancer 38 35 34 800 Yes S CR 84
28 39 F Yes Thyroid cancer 42 30 29 400 Yes S, RT CR 80
29 50 M No Thyroid cancer 52 25 25 800 Yes S, RT CR 79
30 72 M No Urethral cancer 78 61 61 400 Yes RT, CHT Death 65
31 57 M Yes Bladder cancer 59 27 25 400 Yes S CR 87 Bladder cancer 51 S CR 105
32 72 M No Bladder cancer 79 83 82 800 Yes No/palliation Death 86 Bladder cancer 70 CHT, RT CR 117
33 54 F Yes Breast cancer 59 59 58 800 Yes S, CHT CR 82 Breast cancer 46 S, RT, CHT, H CR 156
34 79 M Yes Multiple myeloma 81 18 15 400 Yes CHT Death 46 MGUS 78 No Stable 36
35 74 M Yes Renal cancer 77 25 24 400 Yes RT, CHT Death 48 Renal cancer 74 S CR 28
* The patient subsequently died from progression of CML to blast phase. ID: identification; CML: chronic myeloid leukemia; DX: diagnosis; OM: other malignancy; pM: prior malignancy; DLBCL: dif-
fuse large B-cell lymphoma; MCL: mantle cell lymphoma; MGUS: monoclonal gammopathy of undetermined significance; HU: hydroxyurea; IM: imatinib; S: surgery; CHT: chemotherapy; RT: radio-
therapy; H: hormone therapy; CR: complete remission; CCyR: complete cytogenetic response.
SPM were, therefore, diagnosed in 30/514 (5.8%) patients
(17/309 males, 5.5%; 13/205, 6.2%, females). The estimat-
ed 7-year cumulative incidence of SPM was 6.3% and
8.5% in males and females, respectively (Figure 1A). In
these patients, the median time from CML diagnosis to
SPM diagnosis was 34 (range, 3-80) months, and the medi-
an age at SPM diagnosis was 65 (range, 38-79) years. The
most frequent SPM were colon cancers (n=4), prostate
cancers (n=3), breast cancers (n=2), central nervous system
cancers (n=2), pancreatic cancers (n=2), liver cancers (n=2),
non-Hodgkin lymphomas (n=2), and thyroid cancers
(n=2). No difference in the incidence of SPM was observed
between patients initially treated with high-dose imatinib
(800 mg) versus standard-dose imatinib (400 mg): 9/126
(7.1%) versus 21/388 (5.4%), respectively (P=0.51); more-
over, no patient with SPM received treatment with sec-
ond-generation tyrosine kinase inhibitors or underwent
allogeneic stem cell transplantation. At the time of SPM
diagnosis, all patients were in complete hematologic
remission, 28/30 were in complete cytogenetic remission
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and 27/30 had a major molecular response.
Other malignancies were the second cause of death in
this cohort (19/514; 3.7%), while death from progression
of CML to advanced phase was the first cause (25/514;
4.8%). As expected, patients who developed a SPM had a
significantly lower overall survival rate compared to
patients without a SPM (7-year overall survival: 43.6%
versus 89.9%; P<0.001; Figure 1B). In detail, considering
only the patients with SPM, 16/30 (53%) died because of
the SPM. The median overall survival after diagnosis of
the SPM was 18 months (Figure 1C) and the median age
at death of patients with these malignancies was 66
(range, 53-84) years. All four patients with colon cancer
died within 2 years of diagnosis (after 1, 5, 6, and 24
months). 
Comparison with the general population
We then compared the incidence of SPM, and the relat-
ed mortality, with that reported in the Italian general pop-
ulation, matched by sex and age (Table 4).
In Italy, the standardized incidence of malignancy
between 20 and 84 years of age is 7.6/1.000 and 5.2/1.000
person-years in males and females, respectively. In males,
we observed 17 SPM, and the SIR was 1.06 [95% confi-
dence interval (CI): 0.57 – 1.54]. In females, we observed
13 SPM, which resulted in a SIR of 1.61 (95% CI: 0.92 –
2.31).
In Italy, the standardized mortality for malignancy
between 20 and 84 years of age is 3.5/1.000 and 1.9/1.000
person-years in males and females, respectively. In our
cohort, 9/309 (2.9%) males died of a SPM, and the SMR
was 1.26 (95% CI: 0.53 – 1.99); 7/205 (3.4%) females died
of a SPM, resulting in a statistically significantly higher
SMR (2.41; 95% CI: 1.26 – 3.56).
Discussion
The assessment of SPM risk is particularly complex:
large cohorts of patients, long follow-up, accurate and
comprehensive data collection, and a proper reference
population are required for a good estimation of the risk.
In this context, the analysis of both clinical trials and epi-
demiological registries, although with distinct drawbacks,
provides essential information. 
In our cohort of 514 patients with chronic phase CML
treated in clinical trials with front-line imatinib, with a
median follow-up of 74 months, 30 (5.8%) patients had a
SPM. A higher age at CML diagnosis was the only base-
line factor significantly associated with SPM; reasonably,
it justifies the higher proportion of intermediate-Sokal risk
patients observed in this group. Of note, no CML-related
characteristic was linked to the occurrence of SPM. 
The incidence of SPM among patients with chronic
phase CML was not significantly increased compared to
that in the age- and sex-matched Italian population. These
data confirm the main findings of three large analyses of
CML patients treated with tyrosine kinase inhibitors in
clinical trials (German CML study IV,20 MD Anderson
Cancer Center trial,17 and Novartis global database14) in
which the overall incidence of SPM was similar to that of
the general population. Of note, this conclusion was con-
sistent despite the important differences of these studies
regarding patients’ characteristics (including epidemiolog-
ical aspects), treatments received, and follow-up. Two of
these analyses found higher SIR for some cancers types:
non-Hodgkin lymphomas in the German CML study IV;20
melanoma, kidney and endocrine tumors in the MD
Anderson Cancer Center analysis.17 Unfortunately, in our
study, the relatively low number and the heterogeneity of
the malignancies observed precluded a proper evaluation
of the SIR for different types of cancer. 
In contrast to these data, analysis of the epidemiological
CML Swedish Registry on 868 unselected CML patients
treated with tyrosine kinase inhibitors18 showed an overall
increased SIR for other malignancies (1.52; 95% CI: 1.13 –
1.99); the SIR maintained a statistical significance in
females (1.81; 95% CI: 1.18 – 2.66). It is worth noting that
G. Gugliotta et al.
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Figure 1. Cumulative incidence of second primary malignancies and overall
survival of patients with or without second primary malignancies. (A)
Cumulative incidence of SPM in 514 patients (309 males; 205 females); the
estimated 7-year cumulative incidence was 6.3% and 8.5% in males and
females, respectively; (B) Overall survival (OS) from CML diagnosis: 7-year OS
was 43.6% in patients with SPM (n=30) and 89.9% in patients without SPM
(n=484); P<0.001. (C) OS from SPM diagnosis (n=30): the median OS was 18
months, and the estimated 4-year OS was 42.3% 
A
B
C
we observed a trend for an increased SIR in females (1.6;
lower 95% CI: 0.92).
In our study, progression of CML to advanced phase
and other malignancies were the most common causes of
death (4.8 and 3.7%, respectively). The death rate in
patients with SPM was particularly high (53%), with a rel-
atively short median overall survival (18 months from
diagnosis of the SPM). Of note, in females, the mortality
from SPM was significantly superior to that expected in
the Italian age-matched female population, with a SMR of
2.41 (95% CI: 1.26 – 3.56). 
Despite the limitations due to the small number of
patients, some factors favoring the high mortality
observed for SPM can be hypothesized. For example, the
therapeutic approach to SPM in patients with CML may
be less intensive (6/30 patients received only palliative
care) or the biological behavior of the SPM may be more
aggressive, as a consequence of CML itself, or because of
imatinib. With regards to the latter point, it should be
remembered that in a breast cancer model in mice, treat-
ment with imatinib was associated with an increased
malignant behavior compared to control conditons.29
Moreover, tyrosine kinase inhibitors could enhance, or
facilitate, the progression of SPM through the inhibition of
ABL, which is a downstream effector of the epinephrine
receptors that might have a tumor-suppressor role in
breast, prostate, and colorectal cancers30-32 (interestingly, all
our patients with a colon cancer died) or through impair-
ment of the immune system,6-11 potentially affecting anti-
tumor surveillance. An in-depth evaluation of immunolog-
ical mechanisms might be particularly intriguing in view
of the potential use of new molecules enhancing the
immune system against cancer.
In conclusion, the prevalence of CML is increasing
steadily and this, together with the aging of patients,
means that the number of subjects at risk of developing
SPM is increasing. However, the fact that an increased
incidence was not detectable in the majority of the
cohorts analyzed so far does not support the fear that
chronic treatment with tyrosine kinase inhibitors, in par-
ticular imatinib, cause more SPM compared to those
occurring in the general population. Despite these reassur-
ing results, large studies with a long follow-up (e.g. using
data from CML registries) are warranted to properly
investigate the incidence of specific types of SPM, and to
fully address mortality due to SPM. This could help to
improve patients’ management through early diagnosis of
SPM and treatment optimization in conjunction with
oncologists. Furthermore, the comparison of the incidence
of SPM (and their outcomes) in patients treated with dif-
ferent tyrosine kinase inhibitors may provide important
clues on the potential role of each inhibitor.
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Table 4. Second primary malignancies: comparison of incidence and
mortality with those in the Italian general population, matched by sex
and age*.
Sex Patient- SPM Expected SIR 95% CI
years (N) SPM
M 1806.3 17 16.1 1.06 (0.57; 1.54)
F 1204.8 13 8.1 1.61 (0.92; 2.31)
Deaths Expected SMR 95% CI
(N) deaths
M 1849.4 9 7.2 1.26 (0.53; 1.99)
F 1228.3 7 2.9 2.41 (1.26;
3.56)
* Five-year age classes were considered. We report the overall (20-84 years) ratios,
rather than those for specific age subgroups, to avoid selection biases. SPM: second
primary malignancies; SIR: standardized incidence ratio; SMR: standardized mortality
ratio.
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